Next Article in Journal
Cancer Chemotherapy Specific to Acidic Nests
Next Article in Special Issue
Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
Previous Article in Journal
AR Signaling and the PI3K Pathway in Prostate Cancer
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Cancers 2017, 9(4), 35; doi:10.3390/cancers9040035

Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment

1
Department of Oncology, Drug Discovery Division, Southern Research Institute, Birmingham, AL 35205, USA
2
Protexase Therapeutics, St. Louis, MO 63110, USA
3
Department of Biochemistry and Molecular Biophysics, Alvin J. Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Jill M. Siegfried
Received: 28 February 2017 / Revised: 5 April 2017 / Accepted: 13 April 2017 / Published: 17 April 2017
(This article belongs to the Special Issue Hepatocyte Growth Factor Pathway in Cancer)
View Full-Text   |   Download PDF [2344 KB, uploaded 17 April 2017]   |  

Abstract

The tumor microenvironment plays a key role in tumor development and progression. Stromal cells secrete growth factors, cytokines and extracellular matrix proteins which promote growth, survival and metastatic spread of cancer cells. Fibroblasts are the predominant constituent of the tumor stroma and Hepatocyte Growth Factor (HGF), the specific ligand for the tyrosine kinase receptor c-MET, is a major component of their secretome. Indeed, cancer-associated fibroblasts have been shown to promote growth, survival and migration of cancer cells in an HGF-dependent manner. Fibroblasts also confer resistance to anti-cancer therapy through HGF-induced epithelial mesenchymal transition (EMT) and activation of pro-survival signaling pathways such as ERK and AKT in tumor cells. Constitutive HGF/MET signaling in cancer cells is associated with increased tumor aggressiveness and predicts poor outcome in cancer patients. Due to its role in tumor progression and therapeutic resistance, both HGF and MET have emerged as valid therapeutic targets. Several inhibitors of MET and HGF are currently being tested in clinical trials. Preclinical data provide a strong indication that inhibitors of HGF/MET signaling overcome both primary and acquired resistance to EGFR, HER2, and BRAF targeting agents. These findings support the notion that co-targeting of cancer cells and stromal cells is required to prevent therapeutic resistance and to increase the overall survival rate of cancer patients. HGF dependence has emerged as a hallmark of therapeutic resistance, suggesting that inhibitors of biological activity of HGF should be included into therapeutic regimens of cancer patients. View Full-Text
Keywords: HGF; tumor microenvironment; fibroblasts HGF; tumor microenvironment; fibroblasts
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Owusu, B.Y.; Galemmo, R.; Janetka, J.; Klampfer, L. Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers 2017, 9, 35.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top